A
Alain H. Rook
Researcher at University of Pennsylvania
Publications - 225
Citations - 11608
Alain H. Rook is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Cutaneous T-cell lymphoma & Mycosis fungoides. The author has an hindex of 57, co-authored 213 publications receiving 10771 citations. Previous affiliations of Alain H. Rook include Princeton University & Food and Drug Administration.
Papers
More filters
Journal ArticleDOI
Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
Sean Whittaker,Marie-France Demierre,Ellen J. Kim,Alain H. Rook,Adam Lerner,Madeleine Duvic,Julia Scarisbrick,Sunil Reddy,Tadeusz Robak,Jürgen C. Becker,Alexey Samtsov,William McCulloch,Youn H. Kim +12 more
TL;DR: Romidepsin has significant and sustainable single-agent activity (including improvement in pruritus) and an acceptable safety profile, making it an important therapeutic option for treatment refractory CTCL.
Journal ArticleDOI
Immunopathogenesis and therapy of cutaneous T cell lymphoma
Ellen J. Kim,Stephen D. Hess,Stephen K. Richardson,Sara Newton,Louise C. Showe,Bernice M. Benoit,Ravi Ubriani,Carmela C. Vittorio,Jacqueline M. Junkins-Hopkins,Maria Wysocka,Alain H. Rook +10 more
TL;DR: Recent insights into the pathogenesis and immunobiology of MF/SS are summarized and how these have shaped current therapeutic approaches are summarized, in particular the growing emphasis on enhancement of host antitumor immune responses as the key to successful therapy.
Journal ArticleDOI
Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome.
Alain H. Rook,Henry Masur,H C Lane,Winston R. Frederick,Tadashi Kasahara,Abe M. Macher,Julie Y. Djeu,Jody Manischewitz,L Jackson,Anthony S. Fauci,Gerald V. Quinnan +10 more
TL;DR: Results indicate that IL-2 can substantially potentiate the depressed cytotoxic effector functions of PBL from AIDS patients, while IFN Beta has little effect.
Journal ArticleDOI
Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model
Julia Scarisbrick,H. Miles Prince,Maarten H. Vermeer,Pietro Quaglino,Steven M. Horwitz,Pierluigi Porcu,Rudolf Stadler,Gary S. Wood,Marie Beylot-Barry,Anne Pham-Ledard,Francine M. Foss,Michael Girardi,Martine Bagot,Laurence Michel,Maxime Battistella,Joan Guitart,Timothy M. Kuzel,Maria Estela Martinez-Escala,Teresa Estrach,Evangelia Papadavid,Christina Antoniou,Dimitis Rigopoulos,Vassilki Nikolaou,Makoto Sugaya,Tomomitsu Miyagaki,Robert Gniadecki,José Antonio Sanches,Jade Cury-Martins,Denis Miyashiro,Octavio Servitje,Cristina Muniesa,Emilio Berti,Francesco Onida,Laura Corti,Emilia Hodak,Iris Amitay-Laish,Pablo L. Ortiz-Romero,José Luis Rodríguez-Peralto,Robert Knobler,Stefanie Porkert,Wolfgang Bauer,Nicola Pimpinelli,Vieri Grandi,Richard A Cowan,Alain H. Rook,Ellen Kim,Alessandro Pileri,Annalisa Patrizi,Ramon M. Pujol,Henry K. Wong,Kelly Tyler,René Stranzenbach,Christiane Querfeld,Christiane Querfeld,Paolo Fava,Milena Maule,Rein Willemze,Felicity Evison,Stephen Morris,Robert Twigger,Rakhshandra Talpur,Jinah Kim,G. Ognibene,Shufeng Li,Mahkam Tavallaee,Richard T. Hoppe,Madeleine Duvic,Sean Whittaker,Youn H. Kim +68 more
TL;DR: This study includes the largest cohort of patients with advanced-stage MF/SS and identifies markers with independent prognostic value, which, used together in a prognostic index, may be useful to stratifyadvanced-stage patients.
Journal ArticleDOI
Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial.
Alain H. Rook,Bruce Freundlich,Brian V. Jegasothy,Maritza I. Perez,Walter G. Barr,Sergio A. Jimenez,Robert L. Rietschel,Robert L. Rietschel,Bruce U. Wintroub,M. Bashar Kahaleh,John Varga,Peter Heald,Virginia Steen,Mary C. Massa,George F. Murphy,Charles Perniciaro,Michael Istfan,Samir K. Ballas,Richard L. Edelson +18 more
TL;DR: For patients with systemic sclerosis of recent onset, extracorporeal photochemotherapy is a well-tolerated treatment that may partially reverse the process that results in cutaneous sclerosis.